ER(雌激素受體)兔單克隆抗體

廣州健侖生物科技有限公司

雌激素受體(ER)是一個(gè)66kDa的蛋白質(zhì)，是乳腺生長(zhǎng)和分化重要的調(diào)節(jié)因子。乳腺癌組織中雌激素受體是研究預(yù)后和預(yù)測(cè)內(nèi)分泌治療敏感性的一個(gè)重要參數(shù)。受體水平越多表明抗雌激素藥物治療反應(yīng)性越好。該抗體強(qiáng)烈著色于乳腺癌細(xì)胞的胞核。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

ER(雌激素受體)兔單克隆抗體

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞核

克隆號(hào)：SP1

同型：IgG

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：乳腺癌

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

ER(雌激素受體)兔單克隆抗體

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

對(duì)于某些鐮狀細(xì)胞病的患者而言當(dāng)前沒(méi)有很好的治療方法可供選擇，他們需要接受頻繁的輸血。這項(xiàng)研究代表人們朝著更有效地治療這些患者邁出了重要的一步。研究結(jié)果發(fā)表在一期的《干細(xì)胞》(Stem Cells)雜志上。
這一研究的是霍普金斯大學(xué)血液學(xué)教授、細(xì)胞工程學(xué)研究所成員程臨釗(Linzhao Cheng)博士。他于2012年入選第七批國(guó)家“千人計(jì)劃”。主要研究干細(xì)胞生物學(xué)、人類胚胎干細(xì)胞和其它多能干細(xì)胞,、人類iPS細(xì)胞與重編程、造血干細(xì)胞與造血作用、人類細(xì)胞基因打靶、慢病毒載體與逆轉(zhuǎn)錄病毒載體,基因表達(dá)，調(diào)控與監(jiān)測(cè)、細(xì)胞治療與移植, 基因治療等。
在鐮狀細(xì)胞病中，一種遺傳變異導(dǎo)致了患者的血細(xì)胞不再呈現(xiàn)為典型的圓形，而變?yōu)樾略?或鐮刀)形。這些新月形的細(xì)胞具有粘性，可通過(guò)血管阻塞血流，往往會(huì)造成嚴(yán)重的身體疼痛和虛弱乏力。移植造血骨髓有潛力治愈這一疾病。但對(duì)于一些無(wú)法耐受移植手術(shù)或移植失敗的患者而言，的治療選擇就是定期接受來(lái)自血型匹配健康供體的輸血。
程臨釗說(shuō)，問(wèn)題在于隨著時(shí)間的推移，患者的身體往往會(huì)開(kāi)始啟動(dòng)一種免疫反應(yīng)對(duì)抗外源血液。“他們的身體會(huì)迅速地殺死這些血細(xì)胞，因此他們不得不越來(lái)越頻繁地接受輸血。”

There are currently no good treatments for some patients with sickle cell disease and they need frequent blood transfusions. This research represents an important step towards treating these patients more effectively. The findings are published in the latest issue of Stem Cells.
Leading this research is Dr. Linzhao Cheng, a professor of hematology and a member of the Institute of Cell Engineering at Johns Hopkins University. He was selected for the seventh installment of the National Thousand Talents Program in 2012. Main research stem cell biology, human embryonic stem cells and other pluripotent stem cells, human iPS cells and reprogramming, hematopoietic stem cells and hematopoiesis, human cellular gene targeting, lentiviral and retroviral vectors, gene expression, regulation and monitoring, Cell therapy and transplantation, gene therapy.
In sickle cell disease, a genetic mutation causes the patient's blood cells to no longer appear as a typical circle but into a crescent (or sickle) shape. These crescent-shaped cells are sticky and block blood flow through blood vessels, often causing severe body aches and weakness. Transplantation of hematopoietic marrow has the potential to cure the disease. But for some patients who can not tolerate transplants or fail to transplant, the best treatment option is to regularly receive transfusions from blood-matched healthy donors.
Cheng Lin Zhao said the problem is that over time, the patient's body will often start to start an immune response against exogenous blood. "Their bodies quickly kill these blood cells, so they have to accept blood transfusions more and more frequently."